Condition: Advanced Solid Tumor · Metastatic Solid Tumor · Head and Neck Squamous Cell Carcinoma · Sponsor: InduPro, Inc.
This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced or metastatic squamous and non-squamous NSCLC and other squamous cell solid tumors (for example, head and neck, esophageal, cervical, cutaneous).
This description comes directly from the study's public registry record.
InduPro Inc. · 617-798-1770 · clinicaltrials@induprotx.com
Always discuss trial participation with your own doctor first.
| START Los Angeles | Los Angeles, California, United States | Recruiting |
| Hackensack Meridian - John Theurer Cancer Center | Edison, New Jersey, United States | Not Yet Recruiting |
| START New York Long Island | Lake Success, New York, United States | Recruiting |
| START Dallas Forth Worth | Fort Worth, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07602842